Comprehensive Molecular Tumor Analysis
Advancing Precision Oncology with
Deep Comprehensive Genomic Profiling
Overcoming Cancer’s Complexity
Each patient is unique, and every tumor presents a complex set of alterations across the genome, epigenome, transcriptome, and proteome. This complexity poses significant challenges for cancer treatment, especially for metastatic cancers, cancers of unknown primary (CUP), and rare cancer types. Many patients require comprehensive diagnostics to explore personalized treatment options.
A Comprehensive Solution: Alacris-CMTA®
The Alacris-CMTA® (Comprehensive Molecular Tumor Analysis) solution meets this need by integrating bulk transcriptome (RNA-seq) with whole exome (WES) or whole genome sequencing. This single-test approach captures a broad landscape of actionable insights, empowering clinicians with deeper understanding for treatment planning.
End-to-End Service for Precision Diagnostics
CMTA is offered as a complete, end-to-end service—from sample collection to a detailed, interpreted tumor report designed to aid clinicians in treatment decision-making. The service supports both frozen and formaldehyde-fixed, paraffin-embedded (FFPE) tissue samples, ensuring flexibility across various sample types.
Reliable, Accredited Testing
The CMTA service is operated within the scope of our DIN EN ISO 15189 accredited laboratory, ensuring the highest standards in diagnostic precision and quality.
A Versatile, Tumor-Agnostic Test at a Competitive Price
The CMTA test is suitable for any cancer type, at any stage, and is offered at a competitive price—making it one of the most comprehensive precision oncology tests available today.
Alacris-CMTA®
Comprehensive Molecular Tumor Analysis
In one single report, the CMTA delivers essential information including:
- Gene mutations
- Tumor mutational burden (TMB)
- Chromosome number alterations
- Loss of heterozygosity (LOH)
- Haploinsufficient cancer genes
- Gene amplifications and deletions
- Gene fusions
- Oncogenic transcript isoforms
- Tumor microenvironment
- Snapshot of immune cells infiltration
- Tumor subtype classification
- Prognostic gene expression signatures
The CMTA is flexible and can be adapted to specific requirements on request. Technical specifications and accredited gene list can be downloaded here:
